In a significant move to consolidate the rapidly evolving field of targeted protein degradation, the prestigious academic journal Epigenomics has announced a new Article Collection dedicated to the “Promises and challenges in the development of proteolysis-targeting chimeras (PROTACs) for chromatin modifiers.”
As therapeutic research shifts from traditional enzyme inhibition to the direct degradation of disease-causing proteins, this collection aims to serve as a pivotal resource for researchers bridging the gap between chemical biology and clinical oncology. Spearheaded by guest advisers Dr. Vassiliki Saloura and Dr. William J. Moore from the National Cancer Institute (NCI), the initiative represents a strategic effort to address the complexities of nuclear target degradation.
Main Facts: The Intersection of PROTACs and Epigenetics
The fundamental premise of PROTAC technology is revolutionary: rather than merely occupying the active site of a protein, PROTACs function as bifunctional molecules that recruit E3 ubiquitin ligases to a target protein, tagging it for degradation via the cell’s own proteasome system.
While PROTACs have shown promise in targeting cytosolic proteins, the application of this technology to nuclear chromatin complexes presents unique biological hurdles. Chromatin modifiers—proteins that regulate gene expression through epigenetic markers—are often "undruggable" via conventional small-molecule inhibitors due to their lack of deep binding pockets or structural complexity.
Epigenomics is now seeking submissions that address:
- Chemical Strategies: Novel linker designs and ligand optimization for nuclear permeability.
- Proteomics & Genomics: Advanced methodologies for assessing target specificity and global degradation profiles.
- Therapeutic Efficacy: Emerging clinical and pre-clinical evidence of the degradation of epigenetic targets.
- Technical Hurdles: Innovative approaches to overcoming issues like tissue-specific degradation and the infamous "hook effect."
Chronology: From Concept to Clinical Reality
The trajectory of targeted protein degradation has been characterized by a rapid evolution from academic curiosity to a cornerstone of modern pharmaceutical R&D.
1. The Early Theoretical Phase (2001–2010)
The concept of PROTACs was first introduced by Craig Crews and Raymond Deshaies in 2001. Initially, these were peptide-based, limiting their therapeutic utility. The field spent the following decade refining these molecules into "drug-like" chemical entities.
2. The Small-Molecule Breakthrough (2010–2015)
The introduction of small-molecule E3 ligase recruiters (such as those based on Nutlin or VHL ligands) marked a turning point. Suddenly, the possibility of degrading nuclear proteins—which were previously considered beyond the reach of traditional medicinal chemistry—became a tangible goal.
3. Expansion into Epigenetics (2015–2020)
As the role of epigenetic dysregulation in cancer became clearer, researchers began testing PROTACs against chromatin readers and writers, such as BRD4 and HDACs. The success of these initial studies proved that PROTACs could effectively modulate the epigenome.
4. The Modern Era: Challenges and Optimization (2020–Present)
The field has moved past "proof of concept." Current research is focused on fine-tuning. Today, the focus is on achieving tissue-specific degradation, overcoming resistance mechanisms, and navigating the stoichiometric challenges of nuclear protein concentration. The Epigenomics Article Collection, announced in 2024, acts as a synthesis of this maturation phase, inviting the global community to define the next decade of development.
Supporting Data: Understanding the "Hook Effect" and Selectivity
For researchers entering this space, the primary obstacles remain technical and pharmacological. The Epigenomics call for papers specifically highlights the need for data-driven solutions to the following:
The "Hook Effect"
At the heart of PROTAC efficacy is the formation of a ternary complex: PROTAC-Target-E3 Ligase. However, at high concentrations of the PROTAC molecule, the target protein and the E3 ligase are often bound by different PROTAC molecules simultaneously, preventing the formation of the ternary complex. This "hook effect" results in a bell-shaped dose-response curve, a major challenge in determining therapeutic windows for clinical candidates.
Nuclear Permeability and Specificity
Chromatin is sequestered within the nucleus, necessitating molecules that can bypass the nuclear envelope without causing widespread off-target effects. Data from recent functional genomics studies suggest that the "degradome" is highly context-dependent. A PROTAC that works in a specific cell line may fail in another due to the differential expression of E3 ligases. This collection aims to host papers that utilize high-throughput proteomics to map these interactions.
Official Responses: Guidance from the NCI
The involvement of Dr. Vassiliki Saloura and Dr. William J. Moore from the Center for Cancer Research at the National Cancer Institute provides a level of institutional rigor to the project.
In their capacity as Guest Advisers, their role is to ensure that the submissions selected for this collection represent the highest standards of scientific integrity and translational potential. Their leadership suggests a prioritization of research that can move from the laboratory bench to the clinical trial pipeline. By fostering a dialogue between structural biologists, chemists, and oncologists, the NCI advisers aim to create a cohesive framework for the field, rather than just a disparate set of findings.
Implications: The Future of Epigenetic Therapy
The publication of this Article Collection is not merely an academic exercise; it is an attempt to shape the landscape of cancer treatment.
Shifting the Paradigm of Drug Development
Traditional inhibitors require high affinity for a target, often leading to toxicity when the drug interacts with similar, non-target proteins. PROTACs offer a distinct advantage: because they act as catalysts (the PROTAC is released after the target is degraded), they can theoretically achieve the same therapeutic effect at significantly lower concentrations, potentially reducing side effects.
A Community-Driven Resource
As noted by the Taylor & Francis editorial team, Article Collections function as "key resources" that drive the research community forward. By curating a single space for cutting-edge papers, the journal is accelerating the cross-pollination of ideas. The synergy gained from grouped, high-impact articles often leads to increased citations and visibility, ensuring that the findings are read by the researchers best equipped to build upon them.
Strategic Impact
The move to focus on chromatin modifiers specifically is telling. Epigenetic drugs have historically been difficult to develop because chromatin regulation is a complex, networked process. By focusing on the degradation of these modifiers, scientists are gaining the ability to "turn off" the transcriptional programs that drive oncogenesis.
Conclusion: How to Participate
For those at the forefront of chemical biology, medicinal chemistry, or functional genomics, the Epigenomics Article Collection offers a high-visibility platform to present significant findings.
Submission Guidelines:
Interested contributors are encouraged to reach out to the Commissioning Editor, George Leung, to discuss the suitability of their research. The editorial team is particularly interested in work that addresses the practical limitations of PROTACs, such as:
- Strategies for tissue-specific delivery.
- Advances in the prediction of degradation efficiency using AI and molecular modeling.
- Novel approaches to target validation for previously "undruggable" chromatin complexes.
As the scientific community continues to push the boundaries of what is possible in drug development, the Epigenomics collection stands as a testament to the power of targeted protein degradation. By addressing the "Promises and challenges" of the field, this initiative is poised to become an essential touchstone for the next generation of therapeutic breakthroughs.
To explore the collection’s full scope and access the submission portal, visit the official Taylor & Francis call for papers page.
About the Author
